SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001193125-19-069120
Filing Date
2019-03-08
Accepted
2019-03-08 16:10:33
Documents
8
Period of Report
2019-03-08

Document Format Files

Seq Description Document Type Size
1 6-K d719591d6k.htm 6-K 16549
2 EX-1.1 d719591dex11.htm EX-1.1 225558
3 EX-3.1 d719591dex31.htm EX-3.1 290769
4 EX-5.1 d719591dex51.htm EX-5.1 25677
5 GRAPHIC g719591g0308082827178.jpg GRAPHIC 7690
6 GRAPHIC g719591g0308082827412.jpg GRAPHIC 2991
7 GRAPHIC g719591g0308082941527.jpg GRAPHIC 2991
8 GRAPHIC g719591g0308084957389.jpg GRAPHIC 2968
  Complete submission text file 0001193125-19-069120.txt   583095
Mailing Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900
Business Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900 45 70 22 22 44
Ascendis Pharma A/S (Filer) CIK: 0001612042 (see all company filings)

IRS No.: 000000000 | State of Incorp.: G7 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36815 | Film No.: 19669204
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences